1. Pilot study of plasma creatine riboside as a potential biomarker for cervical cancer
- Author
-
Takahiro Oike, Naoto Osu, Yuya Yoshimoto, Hideru Obinata, Kazuhiro Yoshikawa, Curtis C. Harris, and Tatsuya Ohno
- Subjects
Creatine riboside ,Plasma ,Cervical cancer ,Biomarker ,Oncometabolite ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
This pilot study aimed primarily to evaluate plasma levels of a novel metabolite, creatine riboside, in patients with cervical cancer (discovery and validation cohorts, n = 11 for each) compared with non-cancer subjects (controls, n = 30). We found that the pre-treatment plasma creatine riboside level was significantly higher in the discovery cohort than in controls. The cut-off value determined from the discovery cohort distinguished 90.9% of the patients in the validation cohort from controls. Unbiased principal component analysis of plasma metabolites in high-creatine riboside samples demonstrated enrichment of pathways involved in arginine and creatine metabolism. These data indicate the potential utility of plasma creatine riboside as a biomarker of cervical cancer.
- Published
- 2023
- Full Text
- View/download PDF